- Sector
- Healthcare
- Industry
- Biotechnology
Highlights
- Market Cap
- $16.37B
- Enterprise Value
- $15.65B
- EPS (TTM)
- CN¥3.94
- PE Ratio
- 13.52
- PEG Ratio
- 0.97
- Total Revenue (TTM)
- CN¥40.25B
- Gross Profit (TTM)
- CN¥17.56B
- EBITDA (TTM)
- CN¥14.50B
- Year Range
- $6.20 - $11.21
- ROA (TTM)
- 12.89%
- ROE (TTM)
- 17.38%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
WXXWY Performance Chart
WuXi Biologics (Cayman) Inc (WXXWY) is down 1.8% since the beginning of the year. At $8 per share, WXXWY is trading 29.9% below its 52-week high of $11. Investors who bought $1,000 worth of WXXWY shares 5 years ago would now be looking at an investment worth $221.
Loading charts...
Returns By Period
WuXi Biologics (Cayman) Inc (WXXWY) has returned -1.75% so far this year and 30.08% over the past 12 months.
WuXi Biologics (Cayman) Inc
- 1D
- 0.51%
- 1M
- -5.19%
- YTD
- -1.75%
- 6M
- -7.20%
- 1Y
- 30.08%
- 3Y*
- -6.32%
- 5Y*
- -26.08%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
WXXWY Monthly Returns History
Based on dividend-adjusted daily data since Dec 18, 2017, WXXWY's average daily return is +3.13%, while the average monthly return is +7.92%. At this rate, an investment would double in approximately 0.8 years.
Historically, 49% of months were positive and 51% were negative. The best month was Jan 2019 with a return of +319.6%, while the worst month was Jun 2019 at -68.5%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 8 months.
On a daily basis, WXXWY closed higher 50% of trading days. The best single day was Apr 4, 2018 with a return of +225.0%, while the worst single day was Dec 6, 2018 at -69.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 17.63% | 8.50% | -16.06% | -1.25% | 2.57% | -9.45% | -1.75% | ||||||
| 2025 | 7.96% | 20.35% | 20.47% | -17.46% | 10.14% | 0.79% | 28.66% | 4.01% | 23.50% | -9.86% | -14.38% | -1.23% | 80.69% |
| 2024 | -29.19% | -11.66% | -22.96% | -5.29% | -16.47% | 1.76% | -1.04% | -3.50% | 57.61% | -3.45% | -10.48% | 17.75% | -40.57% |
| 2023 | 10.35% | -16.66% | -10.61% | -3.95% | -14.29% | -5.69% | 20.37% | -3.28% | 3.57% | 6.47% | -10.28% | -32.76% | -50.56% |
| 2022 | -14.80% | -17.08% | -4.29% | -6.81% | -1.62% | 25.60% | 3.95% | -6.75% | -32.33% | -25.23% | 44.47% | 16.55% | -35.71% |
| 2021 | 8.29% | -11.37% | 1.03% | 10.45% | 5.77% | 23.49% | -17.17% | 0.85% | 5.79% | -6.40% | -11.14% | -13.35% | -10.91% |
Benchmark Metrics
WuXi Biologics (Cayman) Inc has an annualized alpha of 215988.90%, beta of 0.59, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since December 18, 2017.
- This stock participated in 59.12% of S&P 500 Index downside but only 57.71% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.59 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 215,988.90%
- Beta
- 0.59
- R²
- 0.00
- Upside Capture
- 57.71%
- Downside Capture
- 59.12%
Return for Risk
Risk / Return Rank
WXXWY ranks 61 for risk / return — better than 61% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for WuXi Biologics (Cayman) Inc (WXXWY) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| WXXWY | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.35 | ||
| Sortino ratioReturn per unit of downside risk | -1.54 | ||
| Omega ratioGain probability vs. loss probability | 1.15 | 1.37 | -0.22 |
| Calmar ratioReturn relative to maximum drawdown | 0.92 | 2.78 | -1.86 |
| Martin ratioReturn relative to average drawdown | 1.74 | 12.44 | -10.70 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the WuXi Biologics (Cayman) Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the WuXi Biologics (Cayman) Inc was 94.03%, occurring on Aug 22, 2024. The portfolio has not yet recovered.
The current WuXi Biologics (Cayman) Inc drawdown is 81.87%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2024 bear market2024 | -94.03%Aug 2024 | 3y 9mo | — | 5y 7moNov 2020 - now |
2019 bear market2019 | -82.40%Jan 2019 | 6mo 15d | 10mo 23d | 1y 5moJun 2018 - Nov 2019 |
2018 bear market2018 | -73.02%May 2018 | 19d | 1mo 21d | 2mo 10dApr 2018 - Jun 2018 |
COVID crash2020 | -69.07%Mar 2020 | 2mo 23d | 9d | 3mo 2dDec 2019 - Mar 2020 |
2018 bear market2018 | -68.89%Feb 2018 | 27d | 20d | 1mo 17dJan 2018 - Feb 2018 |
Drawdown Indicators
| WXXWY | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -94.03% | -56.78% | -37.25% |
Max Drawdown (1Y)Largest decline over 1 year | -32.70% | -9.10% | -23.60% |
Max Drawdown (3Y)Largest decline over 3 years | -80.44% | -18.90% | -61.54% |
Max Drawdown (5Y)Largest decline over 5 years | -93.12% | -25.43% | -67.69% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -81.87% | -1.80% | -80.07% |
Average DrawdownAverage peak-to-trough decline | -64.92% | -10.71% | -54.21% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 17.34% | 2.03% | +15.31% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of WuXi Biologics (Cayman) Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how WuXi Biologics (Cayman) Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for WXXWY, comparing it with other companies in the Biotechnology industry. Currently, WXXWY has a P/E ratio of 13.5. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for WXXWY compared to other companies in the Biotechnology industry. WXXWY currently has a PEG ratio of 1.0. This PEG ratio is higher than the industry average, which may suggest the stock is overvalued relative to its expected earnings growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for WXXWY relative to other companies in the Biotechnology industry. Currently, WXXWY has a P/S ratio of 2.8. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for WXXWY in comparison with other companies in the Biotechnology industry. Currently, WXXWY has a P/B value of 2.3. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with WXXWY
Add WuXi Biologics (Cayman) Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with WXXWY